These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 16513529)

  • 21. Acquired hemophilia in the patient suffering from rheumatoid arthritis: case report.
    Drobiecki A; Pasiarski M; Hus I; Sokołowska B; Wątek M
    Blood Coagul Fibrinolysis; 2013 Dec; 24(8):874-80. PubMed ID: 24042266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A.
    Sharathkumar A; Lillicrap D; Blanchette VS; Kern M; Leggo J; Stain AM; Brooker L; Carcao MD
    J Thromb Haemost; 2003 Jun; 1(6):1228-36. PubMed ID: 12871324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The reversal of inhibitors in congenital hemophilia.
    DeFrates SR; McDonagh KT; Adams VR
    Pharmacotherapy; 2013 Feb; 33(2):157-64. PubMed ID: 23355059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lingual hemorrhage in a patient with hemophilia A complicated by a high titer inhibitor. Management by continuous infusion of monoclonal antibody-purified factor VIII.
    Gordon EM; Mungo R; Goldsmith JC
    Am J Pediatr Hematol Oncol; 1993 Feb; 15(1):107-10. PubMed ID: 8447550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.
    Mariani G; Kroner B;
    Haematologica; 2001 Nov; 86(11):1186-93. PubMed ID: 11694405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune tolerance induction in patients with hemophilia A.
    Astermark J
    Thromb Res; 2011 Jan; 127 Suppl 1():S6-9. PubMed ID: 21056905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of antibodies to factor VIII in hemophilia A patients treated by immune tolerance therapy.
    Scandella D; Reyes H; Felch M; Sakurai Y
    Haematologica; 2000 Oct; 85(10 Suppl):86-8. PubMed ID: 11187882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
    Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
    Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in the clinical management of inhibitors in hemophilia A and B.
    Leissinger CA
    Semin Hematol; 2016 Jan; 53(1):20-7. PubMed ID: 26805903
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.
    Shetty KA; Kosloski MP; Mager DE; Balu-Iyer SV
    Biopharm Drug Dispos; 2016 Oct; 37(7):409-420. PubMed ID: 27418232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiology of inhibitors and current treatment strategies.
    Kreuz W; Ettingshausen CE; Auerswald G; Saguer IM; Becker S; Funk M; Heller C; Klarmann D; Klingebiel T;
    Haematologica; 2003 Jun; 88(6):EREP04. PubMed ID: 12826530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction.
    Leissinger CA
    Am J Hematol; 2004 Oct; 77(2):187-93. PubMed ID: 15389908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Innovating immune tolerance induction for haemophilia.
    Batsuli G; Meeks SL; Herzog RW; Lacroix-Desmazes S
    Haemophilia; 2016 Jul; 22 Suppl 5():31-5. PubMed ID: 27405673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent improvements in the clinical treatment of coagulation factor inhibitors.
    Franchini M; Lippi G
    Semin Thromb Hemost; 2009 Nov; 35(8):806-13. PubMed ID: 20169517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII.
    Matino D; Gargaro M; Santagostino E; Di Minno MN; Castaman G; Morfini M; Rocino A; Mancuso ME; Di Minno G; Coppola A; Talesa VN; Volpi C; Vacca C; Orabona C; Iannitti R; Mazzucconi MG; Santoro C; Tosti A; Chiappalupi S; Sorci G; Tagariello G; Belvini D; Radossi P; Landolfi R; Fuchs D; Boon L; Pirro M; Marchesini E; Grohmann U; Puccetti P; Iorio A; Fallarino F
    J Clin Invest; 2015 Oct; 125(10):3766-81. PubMed ID: 26426076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune tolerance therapy in patients with acquired hemophilia.
    von Depka M
    Hematology; 2004 Aug; 9(4):245-57. PubMed ID: 15621732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current controversies in the formation and treatment of alloantibodies to factor VIII in congenital hemophilia A.
    Kruse-Jarres R
    Hematology Am Soc Hematol Educ Program; 2011; 2011():407-12. PubMed ID: 22160066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors.
    Valentino LA; Kempton CL; Kruse-Jarres R; Mathew P; Meeks SL; Reiss UM;
    Haemophilia; 2015 Sep; 21(5):559-67. PubMed ID: 26032231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunological aspects of inhibitor development.
    Reding MT
    Haemophilia; 2006 Dec; 12 Suppl 6():30-5; discussion 35-6. PubMed ID: 17123391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.